Journal article
Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension
V Thakkar, M Nikpour, WM Stevens, SM Proudman
Internal Medicine Journal | WILEY | Published : 2015
DOI: 10.1111/imj.12691
Abstract
Pulmonary arterial hypertension (PAH) is a leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Approximately one in 10 will develop PAH during their lifetime. These patients have a worse prognosis than those with PAH due to other causes. The most common clinical feature of SSc-PAH in the early stages is non-specific exercise intolerance that can be erroneously attributed to other manifestations of SSc. Screening provides an opportunity for early identification of SSc-PAH and prompt initiation of therapies with the potential to improve quality of life and survival. International guidelines recommend annual transthoracic Doppler echocardiography (TTE), but TTE h..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The authors are members of the Australian Scleroderma Interest Group, which receives funding from Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. V. Thakkar was funded by a National Health and Medical Research Council of Australia Scholarship (APP1038612) and The Australian Scleroderma Interest Group Clinical Research Fellowship. M. Nikpour holds a David Bickart Clinician Research Fellowship from the University of Melbourne, Faculty of Medicine, Dentistry and Health Sciences and is a recipient of a National Health and Medical Research Council of Australia Clinical Research Fellowship (APP1071735).